PMID- 29330620
OWN - NLM
STAT- MEDLINE
DCOM- 20180524
LR  - 20220321
IS  - 1432-5233 (Electronic)
IS  - 0940-5429 (Print)
IS  - 0940-5429 (Linking)
VI  - 55
IP  - 4
DP  - 2018 Apr
TI  - Impact of sirtuin-1 expression on H3K56 acetylation and oxidative stress: a 
      double-blind randomized controlled trial with resveratrol supplementation.
PG  - 331-340
LID - 10.1007/s00592-017-1097-4 [doi]
AB  - AIMS: Sirtuin-1 (SIRT-1) down-regulation in type 2 diabetes mellitus (T2DM) has 
      been associated with epigenetic markers of oxidative stress. We herein aim to 
      evaluate whether an increase in SIRT-1 expression affects histone 3 acetylation 
      at the 56 lysine residue (H3K56ac) in T2DM patients randomly selected to receive 
      either resveratrol (40 mg or 500 mg) or a placebo for 6 months. The primary 
      outcome is changes in the H3K56ac level by variation in SIRT-1 expression and the 
      secondary outcome is the evidence of association between SIRT-1 level, 
      antioxidant markers (TAS), and metabolic variables. METHODS AND RESULTS: At 
      baseline, peripheral blood mononuclear cell H3K56ac values among the SIRT-1 
      tertiles did not differ. At trial end, SIRT-1 levels were significantly higher in 
      patients receiving 500 mg resveratrol. At follow-up, patients were divided into 
      tertiles of delta (trial end minus baseline) SIRT-1 value. Significant reductions 
      in H3K56ac and body fat percentage were found in the highest tertile as were 
      increased TAS levels. A multiple logistic regression model showed that the 
      highest delta SIRT-1 tertile was inversely associated with variations in H3K56ac 
      (OR = 0.66; 95% CI 0.44-0.99), TAS (OR = 1.01; 95% CI 1.00-1.02), and body fat 
      percentage (OR = 0.75; 95% CI 0.58-0.96). CONCLUSIONS: We provide new knowledge 
      on H3K56ac and SIRT-1 association in T2DM. These data suggest that boosting 
      SIRT-1 expression/activation may impact redox homeostasis in these patients. 
      ClinicalTrials.gov Identifier NCT02244879.
FAU - Bo, Simona
AU  - Bo S
AD  - Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126, 
      Turin, Italy.
FAU - Togliatto, Gabriele
AU  - Togliatto G
AD  - Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126, 
      Turin, Italy.
FAU - Gambino, Roberto
AU  - Gambino R
AD  - Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126, 
      Turin, Italy.
FAU - Ponzo, Valentina
AU  - Ponzo V
AD  - Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126, 
      Turin, Italy.
FAU - Lombardo, Giusy
AU  - Lombardo G
AD  - Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126, 
      Turin, Italy.
FAU - Rosato, Rosalba
AU  - Rosato R
AD  - Department of Psychology, University of Turin, Turin, Italy.
FAU - Cassader, Maurizio
AU  - Cassader M
AD  - Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126, 
      Turin, Italy.
FAU - Brizzi, Maria Felice
AU  - Brizzi MF
AUID- ORCID: 0000-0003-0944-6992
AD  - Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126, 
      Turin, Italy. mariafelice.brizzi@unito.it.
LA  - eng
SI  - ClinicalTrials.gov/NCT02244879
PT  - Journal Article
PT  - Observational Study
PT  - Randomized Controlled Trial
DEP - 20180112
PL  - Germany
TA  - Acta Diabetol
JT  - Acta diabetologica
JID - 9200299
RN  - 0 (Antioxidants)
RN  - 0 (Histones)
RN  - 0 (Stilbenes)
RN  - EC 3.5.1.- (Sirtuin 1)
RN  - Q369O8926L (Resveratrol)
SB  - IM
MH  - Acetylation/drug effects
MH  - Adult
MH  - Aged
MH  - Antioxidants/*pharmacology
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/*metabolism
MH  - Dietary Supplements
MH  - Double-Blind Method
MH  - Down-Regulation
MH  - Female
MH  - Histones/*metabolism
MH  - Humans
MH  - Leukocytes, Mononuclear/drug effects/metabolism
MH  - Male
MH  - Middle Aged
MH  - Oxidative Stress/drug effects/*physiology
MH  - Resveratrol
MH  - Sirtuin 1/*metabolism
MH  - Stilbenes/administration & dosage/*pharmacology
PMC - PMC5851693
OTO - NOTNLM
OT  - Epigenetics
OT  - PBMC
OT  - Resveratrol
OT  - Sirtuin-1
COIS- CONFLICTS OF INTEREST: The authors report no conflict of interest. ETHICAL 
      APPROVAL: All procedures performed in studies involving human participants were 
      in accordance with the ethical standards of the institutional and/or national 
      research committee and with the 1964 Helsinki Declaration and its later 
      amendments or comparable ethical standards. INFORMED CONSENT: Informed consent 
      was obtained from all individual participants included in the study.
EDAT- 2018/01/14 06:00
MHDA- 2018/05/25 06:00
PMCR- 2018/01/12
CRDT- 2018/01/14 06:00
PHST- 2017/11/13 00:00 [received]
PHST- 2017/12/29 00:00 [accepted]
PHST- 2018/01/14 06:00 [pubmed]
PHST- 2018/05/25 06:00 [medline]
PHST- 2018/01/14 06:00 [entrez]
PHST- 2018/01/12 00:00 [pmc-release]
AID - 10.1007/s00592-017-1097-4 [pii]
AID - 1097 [pii]
AID - 10.1007/s00592-017-1097-4 [doi]
PST - ppublish
SO  - Acta Diabetol. 2018 Apr;55(4):331-340. doi: 10.1007/s00592-017-1097-4. Epub 2018 
      Jan 12.